{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:00:12Z","timestamp":1778814012082,"version":"3.51.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Pelvic hypoperfusion caused by atherosclerosis has been proposed as a cause of lower urinary tract dysfunction including overactive bladder syndrome (OAB). Limited data indicate that OAB patients with concomitant diabetes or hypertension, known risk factors of atherosclerosis, may exhibit greater baseline OAB symptoms and slightly smaller therapeutic responses to treatment, but the impact of a combined presence of diabetes and hypertension has not been reported. Therefore, we have explored whether the combined presence of both comorbidities is associated with greater baseline OAB symptoms than that of either comorbidity alone. Secondary questions were exploration of the impact of either comorbidity on baseline symptoms, and of the impact of either comorbidity alone and their combination on therapeutic responses.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Data from two non-interventional studies applying treatment with propiverine ER 30 or 45\u00a0mg\/d for 12\u00a0weeks were analyzed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Number of urgency episodes in the combination group was greater than with each comorbidity alone. The impact of comorbidities on baseline intensity of incontinence, frequency or nocturia or Patient Perception of Bladder Condition was less consistent or absent. Either comorbidity alone was associated with a smaller % improvement of symptoms, and their combination had a greater effect than either alone. However, all attenuations associated with comorbidity were small relative to the overall improvement. <\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> We conclude that comorbidities of diabetes and hypertension have detectable effects on OAB symptoms and treatment responses, but the small magnitude of these alterations does not justify changing existing paradigms for the clinical management of OAB.<\/jats:p>","DOI":"10.3389\/fphar.2023.1144470","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T05:30:36Z","timestamp":1680154236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients"],"prefix":"10.3389","volume":"14","author":[{"given":"A. Elif","family":"M\u00fcderrisoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse A.","family":"Sakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Murgas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean J. M. C. H.","family":"de la Rosette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/nau.24275","article-title":"Do overactive bladder symptoms and their treatment-associated changes exhibit a normal distribution? Implications for analysis and reporting","volume":"39","author":"Amiri","year":"2020","journal-title":"Neurourol. Urodynamics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/jcm10020311","article-title":"Factors associated with decisions for initial dosing, up-titration of propiverine and treatment outcomes in overactive bladder syndrome patients in a non-interventional setting","volume":"10","author":"Amiri","year":"2021","journal-title":"J. Clin. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","article-title":"Scientists rise up against statistical significance","volume":"567","author":"Amrhein","year":"2019","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/nau.23490","article-title":"A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin-induced rat models","volume":"37","author":"Arioglu-Inan","year":"2018","journal-title":"Neurourol. Urodynamics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/ijcp.12518","article-title":"Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies","volume":"69","author":"Bunn","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1097\/00005392-199904000-00098","article-title":"Altered NGF regulation may link a genetic predisposition for hypertension with hyperactive voiding","volume":"161","author":"Clemow","year":"1999","journal-title":"J. Urology"},{"key":"B7","unstructured":"The overactive bladder\n            DimpflT.\n            K\u00f6lblH.\n            PeschersU.\n            PetriE.\n            Gauruder-BurmesterA.\n            H\u00f6fnerK.\n          2010"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1002\/nau.23786","article-title":"A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences","volume":"37","author":"Ellenbroek","year":"2018","journal-title":"Neurourol. Urodynamics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00210-022-02249-9","article-title":"Established and emerging treatments for diabetes-associated lower urinary tract dysfunction","volume":"395","author":"Erdogan","year":"2022","journal-title":"Naunyn Schmiedeb. Arch. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1159\/000448484","article-title":"The relationship between the clinical progression of benign prostatic hyperplasia and metabolic syndrome: A prospective study","volume":"97","author":"Fu","year":"2016","journal-title":"Urol. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1590\/S1677-55382012000500010","article-title":"Detrusor overactivity in diabetic and non-diabetic patients: Is there a difference?","volume":"38","author":"Golabek","year":"2012","journal-title":"Int. Braz. J. Urology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.urology.2006.09.034","article-title":"Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: A prospective cohort study of air force veterans","volume":"68","author":"Gupta","year":"2006","journal-title":"Urology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/aje\/kwg051","article-title":"Risk factors for lower urinary tract symptoms in a population-based sample of African-American men","volume":"157","author":"Joseph","year":"2003","journal-title":"Am. J. Epidemiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/dmrr.1223","article-title":"Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes","volume":"27","author":"Kempler","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/pcan.2014.22","article-title":"Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men","volume":"17","author":"Marshall","year":"2014","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00345-010-0605-8","article-title":"Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men","volume":"29","author":"Martin","year":"2011","journal-title":"World J. Urology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/s0895-4356(01)00351-1","article-title":"Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men","volume":"54","author":"Meigs","year":"2001","journal-title":"J. Clin. Epidemiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00002018-200427050-00005","article-title":"Safety of telmisartan in patients with arterial hypertension. An open-label observational study","volume":"27","author":"Michel","year":"","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00210-015-1137-y","article-title":"Are blood vessels a target to treat lower urinary tract dysfunction?","volume":"388","author":"Michel","year":"2015","journal-title":"Naunyn-Schmiedeberg's Archives Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1081074","DOI":"10.3389\/fphar.2022.1081074","article-title":"Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses","volume":"13","author":"Michel","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/01.ju.0000139995.85780.d8","article-title":"Association of hypertension with symptoms of benign prostatic hyperplasia","volume":"172","author":"Michel","year":"","journal-title":"J. Urology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0022-5347(01)62787-3","article-title":"Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: Does comorbidity alter tolerability?","volume":"160","author":"Michel","year":"1998","journal-title":"J. Urology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1097\/00005392-200006000-00021","article-title":"Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia","volume":"163","author":"Michel","year":"2000","journal-title":"J. Urology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/dmd.119.090027","article-title":"New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology","volume":"48","author":"Michel","year":"","journal-title":"Drug Metabolism Dispos."},{"key":"B25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/mol.119.118927","article-title":"New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology","volume":"97","author":"Michel","year":"","journal-title":"Mol. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0022-5347(05)64567-3","article-title":"Do gender or age affect the efficacy and safety of tolterodine?","volume":"168","author":"Michel","year":"2002","journal-title":"J. Urology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"816","DOI":"10.3389\/fphar.2020.00816","article-title":"Factors associated with nocturia-related quality of life in men with lower urinary tract symptoms and treated with tamsulosin oral controlled absorption system in a non-interventional study","volume":"11","author":"Michel","year":"","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2165\/00002018-200831060-00005","article-title":"Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: A 12-week, open-label, post-marketing surveillance study","volume":"31","author":"Michel","year":"2008","journal-title":"Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/bjp.2008.39","article-title":"Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces \u00df3-adrenoceptor-mediated relaxation, causing rat detrusor overactivity","volume":"153","author":"Monica","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s12325-022-02114-4","article-title":"What are realistic expectations to become free of overactive bladder symptoms? Experience from non-interventional studies with propiverine","volume":"39","author":"M\u00fcderrisoglu","year":"2022","journal-title":"Adv. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"R1366","DOI":"10.1152\/ajpregu.1998.275.4.R1366","article-title":"Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats","volume":"275","author":"Persson","year":"1998","journal-title":"Am. J. Physiology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2006.01.031","article-title":"The association between vascular risk factors and lower urinary tract symptoms in both sexes","volume":"50","author":"Ponholzer","year":"2006","journal-title":"Eur. Urol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"959285","DOI":"10.3389\/fcvm.2022.959285","article-title":"Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment","volume":"9","author":"Poznyak","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/nau.21074","article-title":"Characterization of the urinary bladder dysfunction in renovascular hypertensive rats","volume":"30","author":"Ramos-Filho","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"B36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/sj.ijo.0802881","article-title":"Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III)","volume":"29","author":"Rohrmann","year":"2005","journal-title":"Int. J. Obes."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/j.1742-1241.2010.02442.x","article-title":"Do gender, age or life style factors affect responses to anti-muscarinic treatment in overactive bladder patients?","volume":"64","author":"Schneider","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/ijcp.12196","article-title":"Does concomitant diabetes affect treatment responses in overactive bladder patients?","volume":"67","author":"Schneider","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/nau.24960","article-title":"Associations between the Patient Perception of Bladder Condition score and overactive bladder syndrome symptoms at baseline and upon treatment","volume":"41","author":"Sch\u00f6nburg","year":"2022","journal-title":"Neurourol. Urodyn."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00228-021-03148-3","article-title":"Trends and patterns in EU(7)-PIM prescribing to elderly patients in Germany","volume":"77","author":"Selke Krulichov\u00e1","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/s0006-8993(98)00061-4","article-title":"Neurally mediated hyperactive voiding in spontaneously hypertensive rats","volume":"790","author":"Spitsbergen","year":"1998","journal-title":"Brain Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1469-445x.1999.tb00079.x","article-title":"The spontaneously hypertensive rat: Insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males","volume":"84","author":"Steers","year":"1999","journal-title":"Exp. Physiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"F738","DOI":"10.1152\/ajprenal.00333.2015","article-title":"LUTS in pelvic ischemia: A new concept in voiding dysfunction","volume":"310","author":"Thurmond","year":"2016","journal-title":"Am. J. Physiology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41592-022-01615-y","article-title":"The EQIPD framework for rigor in the design, conduct, analysis and documentation of animal experiments","volume":"19","author":"Vollert","year":"2022","journal-title":"Nat. Methods"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e100046","DOI":"10.1136\/bmjos-2019-100046","article-title":"Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals","volume":"4","author":"Vollert","year":"2020","journal-title":"BMJ Open Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"923555","DOI":"10.3389\/fphys.2022.923555","article-title":"Analysis of 16 studies in nine rodent models does not support the hypothesis that diabetic polyuria is a main reason of urinary bladder enlargement","volume":"13","author":"Yesilyurt","year":"2022","journal-title":"Front. Physiology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.eururo.2014.12.012","article-title":"A population-based survey of the prevalence, potential risk factors, and symptom-specific bother of lower urinary tract symptoms in adult Chinese women","volume":"68","author":"Zhang","year":"2015","journal-title":"Eur. Urol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1144470\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T05:30:39Z","timestamp":1680154239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1144470\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":47,"alternative-id":["10.3389\/fphar.2023.1144470"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1144470","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"article-number":"1144470"}}